Seminer in Medicine / Dr. Nülifer Kılıç Durankuş

Author: KUSOM
Time: 14:00




Wednesday, June 16th, 2021

Speaker:                Dr. Nülifer Kılıç Durankuş – Department of Radiation Oncology, Koç University Hospital

Title:                     Targeted Ablative Radiotherapy: Sbrt

Time:                    14:00


Meeting ID:            992 4612 3055

Passcode:             907165




  “Stereotactic body radiotherapy (SBRT)” also known as “Stereotactic ablative radiation therapy (SABR)” is an advanced image -guided, highly specialized, and precise technique of radiotherapy to deliver high focal ablative doses to any required target extra-cranially, within similar principles of cranial radiosurgery practiced for decades. The treatment course is within 3-10 fractions, mainly completed in 3 or 4 fractions, instead of conventional radiotherapy of 6 to 8 weeks.

  In comparison to standard radiotherapy techniques, SBRT should demand a dedicated team and an experienced setting for safe delivery of very high doses per fraction with very small margins to control tumor and to spare organs at risk; in addition to advanced technologies including specially equipped linear accelerators, motion management protocols, on board imaging methods, and enhanced dose planning algorithms (IMRT, VMAT, etc). On this context, era of SBRT allows us to take place in management of early stage cancers such as Lung or Prostate tumors with curative intent, as well as to ablate or consolidate oligo-metastatic diseases based on tumor board discussions to increase disease specific and hopefully overall survival. Highly targeted radiotherapy, SBRT, is included in many ongoing treatment protocols to control oligo-metastases to increase disease free survival under same systemic treatment, to delay administration of further systemic complicated treatments, to decrease tumor load, to enhance immunotherapeutic responses, to fight with chemo/targeted drug-resistance and to improve the quality of life in different settings. Equipped with SBRT as a non-invasive, well tolerated, short term treatment without hospitalization, we encourage our multidisciplinary team to consider SBRT as a viable alternative to surgery in different metastatic sites, as well as a primary treatment choice in medically inoperable or borderline early stage cancers.